Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock

Thursday, 14 January 2021, 01:03:00
RED BANK, N.J., Jan. 13, 2021 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,250,000 shares of its…
— PR Newswire

The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations

Wednesday, 13 January 2021, 13:25:38
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) AbbVie Inc (NYSE: ABBV ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alkermes Plc (NASDAQ: ALKS ) AtriCure Inc. (NASDAQ: ATRC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) BIOLASE Inc (NASDAQ: BIOL ) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) CareDx Inc (NASDAQ: CDNA ) Celsius Holdings, Inc. (NASDAQ: CELH ) DermTech Inc (NASDAQ: DMTK ) Dyne Therapeutics Inc (NASDAQ: DYN ) Edap Tms SA (NASDAQ: EDAP ) Evelo Biosciences Inc (NASDAQ: EVLO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Eyenovia Inc (NASDAQ: EYEN ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Guardant Health Inc (NASDAQ: GH ) (reacted to presentation at the JPMorgan Healthcare Conference) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Laboratory Corp.
— Benzinga

Provention Bio Announces Proposed Public Offering of Common Stock

Tuesday, 12 January 2021, 22:26:00
RED BANK, N.J., Jan. 12, 2021 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock….
— PR Newswire

Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference

Wednesday, 6 January 2021, 22:05:00
RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the H.C. Wainwright…
— PR Newswire

Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals

Monday, 4 January 2021, 13:00:00
RED BANK, N.J., Jan. 4, 2021 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Biologics License Application (BLA) for teplizumab for the delay or prevention of…
— PR Newswire